ACR适宜性标准®:膀胱癌治疗后的监测
该指南由美国放射学会(ACR)制定,针对膀胱尿路上皮癌治疗后监测影像检查的适宜性提出推荐。患者按非肌层浸润性膀胱癌无/有症状或附加危险因素、肌层浸润性膀胱癌分为三组。指南基于文献分析与RAND/UCLA适宜性方法及GRADE分级,在证据不足时辅以专家意见。
要点
- 监测影像目标:发现新发或先前未检出的尿路上皮肿瘤、识别转移性疾病、评估治疗并发症。
- 患者分层:非肌层浸润性膀胱癌无/有症状或附加危险因素、肌层浸润性膀胱癌三组。
- 推荐采用RAND/UCLA适宜性方法和GRADE对影像检查适宜性进行评级。
核心结论
- 膀胱尿路上皮癌治疗后监测影像旨在发现新发或先前未检出的尿路上皮肿瘤、识别转移性疾病并评估治疗并发症。
- 监测患者可分为三组:非肌层浸润性膀胱癌无/有症状或附加危险因素、肌层浸润性膀胱癌。
研究设计与样本
- 美国放射学会(ACR)适宜性标准为循证指南,由多学科专家小组每年审查。
- 指南制定与修订包括对同行评审期刊当前医学文献的广泛分析,并应用RAND/UCLA适宜性方法和GRADE评级。
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
诊断标准与关键数值
- 按非肌层浸润性膀胱癌无/有症状或附加危险因素、肌层浸润性膀胱癌三组进行监测影像适宜性评级。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: (1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; (2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and (3) muscle invasive bladder cancer. This article is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
引用
- Allen BC, Oto A, Akin O, et al. ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer. J Am Coll Radiol. 2019. PMID: 31685109. doi:10.1016/j.jacr.2019.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。